Nov 17 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN TECHNOLOGIES, INC. REPORTS FIRST QUARTER FISCAL
YEAR
2021 RESULTS AND PROVIDES BUSINESS UPDATE
* Q1 LOSS PER SHARE $0.02
* FROM JULY 25 TO SEPT 30 VYLEESI GROSS SALES $809,100
* PHASE 2 CLINICAL RESULTS OF PL9643 FOR TREATMENT OF DRY
EYE
DISEASE ON TRACK FOR DECEMBER 2020
* ANTICIPATES FILING AN IND & COMMENCING CLINICAL TRIALS
WITH
PL8177 FOR NON-INFECTIOUS UVEITIS, , IN H2 OF CALENDAR YEAR 2021
* PALATIN TECHNOLOGIES -CONTINUES ITS WORK RELATED TO
TREATMENT OF
PATIENTS WITH DIABETIC RETINOPATHY, WITH IND FILING TARGETED FOR
MID-CALENDAR YEAR 2021
* PALATIN TECHNOLOGIES- TO POTENTIALLY FILE AN IND WITH FDA,
INITIATE A CLINICAL STUDY OF PL8177 FOR TREATMENT OF COVID-19
PATIENTS EARLY IN Q1 OF 2021
Source text for Eikon: urn:newsml:reuters.com:*:nL8N2I3493
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))